21:53 , May 29, 2019 |  BC Extra  |  Company News

Management tracks: Gilead replaces Hamill with BMS's Mercier; plus Alnylam, Audentes and more

Gilead Sciences Inc. (NASDAQ:GILD) hired Johanna Mercier as chief commercial officer, effective July 1, to assume the responsibilities of Laura Hamill, who is leaving nine months after joining the company as EVP of worldwide commercial...
22:35 , May 17, 2019 |  BC Extra  |  Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20  Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
21:44 , Feb 12, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
23:31 , Dec 21, 2018 |  BC Extra  |  Company News

Alexion gains early approval for long-acting PNH therapy

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received FDA approval for Ultomiris ravulizumab-cwvz (ALXN1210), the biotech's long-acting formulation of Soliris eculizumab, to treat paroxysmal nocturnal hemoglobinuria. While the approval came nearly two months ahead of the Feb. 18...
19:26 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
00:47 , Dec 19, 2018 |  BC Extra  |  Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
23:21 , Sep 10, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
23:45 , Aug 21, 2018 |  BC Extra  |  Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
22:48 , May 3, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Sangamo

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said CEO Milind Deshpande will step down. He will be succeeded by President and COO Joseph Truitt. Sangamo Therapeutics Inc. (NASDAQ:SGMO) said SVP and CBO Curt Herberts, III...